Immune cells in non-spreading rectal cancer treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study is looking at immune cells (NK cells and ImmunoScore) in the blood of people with rectal cancer that hasn't spread. It may help doctors learn more about how the immune system responds to standard chemoradiation treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with rectal adenocarcinoma (a type of rectal cancer)
- Your cancer is at stage cT2-4N0 or cT1-T4N+ (has not spread to distant parts of the body, may involve nearby lymph nodes)
- Your planned treatment includes standard chemoradiation (radiation plus capecitabine) with or without additional contact therapy, and possibly chemotherapy before radiation
- You do not have metastatic disease (cancer that has spread to other organs)
- You have not had pelvic radiation before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This study looks at how rectal cancer responds to the usual chemotherapy and radiation given before surgery. It aims to learn if certain molecular features of your tumor can predict how well it responds to treatment.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.